SI-BONE, Inc.® Announces iFuse Implant System® Receives Indication Cleared by the FDA that Includes Improved Pain, Patient Function and Quality of Life at 12-Months FDA clearance and triangular-shape with published safety and effectiveness data differentiates it from competitors

SAN JOSE, Calif., Nov. 9, 2015 /PRNewswire/ -- SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that the US Food and Drug Administration (FDA) has cleared the iFuse Implant System to include in its indication statement that "Clinical studies have demonstrated that treatment with the iFuse Implant System improved pain, patient function and quality of life at 12 months post-implantation."  This addition was based on prospective and retrospective clinical studies...